SCHEMBL4242035

SCHEMBL4242035

COc1ccc2nc(-c3ccccc3F)n(NCc3ccc(Br)cc3)c(=O)c2c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.65
MDM2 Q00987 1/20 0.65
MAPT P10636 4/20 0.54
NPSR1 Q6W5P4 3/20 0.54
CYP1A2 P05177 2/20 0.54
CYP3A4 P08684 2/20 0.54
CYP2D6 P10635 2/20 0.54
CYP2C9 P11712 2/20 0.54
CYP2C19 P33261 2/20 0.54
HTT P42858 3/20 0.49
LMNA P02545 3/20 0.49
MEN1 O00255 4/20 0.44
KMT2A Q03164 4/20 0.44
POLB P06746 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.43
GAA P10253 1/20 0.43
HPGD P15428 1/20 0.43
F2RL1 P55085 1/20 0.43
KDM4E B2RXH2 1/20 0.43
GPR35 Q9HC97 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4233268 0.85 ALDH1A1 (0.58) ALDH1A1MDM2MAPTNPSR1CYP1A2
SCHEMBL4236257 0.83 ALDH1A1 (0.70) ALDH1A1MDM2MAPTNPSR1CYP1A2
SCHEMBL4238037 0.83 ALDH1A1 (0.52) ALDH1A1MDM2MAPTNPSR1CYP1A2
SCHEMBL4237558 0.79 CYP1A2 (0.60) ALDH1A1MDM2MAPTNPSR1CYP1A2
SCHEMBL4233303 0.79 ALDH1A1 (0.47) ALDH1A1MDM2MAPTNPSR1CYP1A2
SCHEMBL4233437 0.78 LMNA (0.75) ALDH1A1MDM2MAPTNPSR1CYP1A2
SCHEMBL4241360 0.78 ALDH1A1 (0.62) ALDH1A1MDM2MAPTNPSR1CYP1A2
SCHEMBL4242039 0.78 NPSR1 (0.66) ALDH1A1MDM2MAPTNPSR1CYP1A2
SCHEMBL4238641 0.77 NPSR1 (0.61) ALDH1A1MDM2MAPTNPSR1CYP1A2
SCHEMBL4237779 0.77 ALDH1A1 (0.61) ALDH1A1MDM2MAPTNPSR1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090035306-A1 QUINAZOLINONE MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-02-05 US disclosed
US-20090035306-A1 QUINAZOLINONE MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-02-05 US disclosed
US-20090035306-A1 QUINAZOLINONE MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-02-05 US disclosed
WO-2008067219-A2 QUINAZOLINONE MODULATORS OF TGR5 KALYPSYS, INC. (US) 2008-06-05 WO disclosed
WO-2008067219-A2 QUINAZOLINONE MODULATORS OF TGR5 KALYPSYS, INC. (US) 2008-06-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090035306-A1 QUINAZOLINONE MODULATORS OF TGR5 GRK5, PLAAT5, GPBAR1 ALDH1A1 3192/4885MDM2 4740/4885MAPT 4430/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.